Cancer Family
Mediastinal Neoplasm
CI-CAN-00000259Explore in graph →
Non-malignant69 active trials1 approved drugs
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000259Explore in graph →
Clinical trials
162 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02362035 | ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies(KEYNOTE145) | completed | Phase 1 / Phase 2 | 161 | Acerta Pharma BVINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT03035331 | Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 11 | Mayo ClinicOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT01516567 | Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation | completed | Phase 2 | 47 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 9 | Feb 9, 2026 | clinicaltrials |
| NCT03210662 | Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04875195 | A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) | completed | Phase 2 | 66 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Oct 29, 2025 | clinicaltrials |
| NCT00001337 | Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 348 | National Cancer Institute (NCI)NIH | 1 | Jun 22, 2025 | clinicaltrials |
| NCT03484819 | Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04432506 | Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma | completed | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT02348216 | Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma(ZUMA-1) | completed | Phase 1 / Phase 2 | 307 | Kite, A Gilead CompanyINDUSTRY | 6 | Jun 4, 2024 | clinicaltrials |
| NCT01897571 | Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL | completed | Phase 1 / Phase 2 | 400 | Epizyme, Inc.INDUSTRY | 10 | Mar 26, 2024 | clinicaltrials |
| NCT02576990 | Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) | completed | Phase 2 | 80 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 27, 2023 | clinicaltrials |
| NCT04323657 | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 6 | TCR2 TherapeuticsINDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT00924326 | CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2022 | clinicaltrials |
| NCT01965119 | Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma(JAK2) | completed | Phase 2 | 20 | Samsung Medical CenterOTHER | 1 | Nov 1, 2018 | clinicaltrials |
| NCT02423291 | A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL(FIL_SGN01) | completed | Phase 2 | 15 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 26, 2017 | clinicaltrials |
| NCT00532259 | CT-011 MAb in DLBCL Patients Following ASCT | completed | Phase 2 | 72 | CureTech LtdINDUSTRY | 3 | Sep 12, 2014 | clinicaltrials |
| NCT00558220 | R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas(R-MCEB) | completed | Phase 2 | 106 | Czech Lymphoma Study GroupOTHER | 1 | Nov 14, 2007 | clinicaltrials |
Data updated 22 days agoSource updated May 13, 2026source: clinicaltrials